Reviva Pharmaceuticals Holdings, Inc.
General ticker "RVPH" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $614.6M (TTM average)
Reviva Pharmaceuticals Holdings, Inc. does not follow the US Stock Market performance with the rate: -24.8%.
Estimated limits based on current volatility of 7.1%: low 0.53$, high 0.61$
Factors to consider:
- Total employees count: 15 (+50.0%) as of 2023
- Company does not operate outside North America (retrieved using AI)
- Top business risk factors: Dependence on single product candidate, Operational and conduct risks, Pandemic risks, Liquidity and credit risks, Strategic risks and growth management
- Current price 88.4% below estimated low
- Earnings for 3 months up through Q1 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [5.03$, 17.61$]
- 2026-12-31 to 2027-12-31 estimated range: [4.11$, 14.71$]
Financial Metrics affecting the RVPH estimates:
- Positive: with PPE of 20.2 at the end of fiscal year the price was low
- Negative: negative Operating cash flow
- Negative: negative Operating income
- Negative: negative Net income
- Negative: negative Industry operating income (median)
- Positive: Investing cash flow per share per price, % of 0 > -0.60
- Positive: 42.59 < Shareholder equity ratio, % of 54.31 <= 64.29
- Positive: Interest expense per share per price, % of 0.04 <= 0.73
Short-term RVPH quotes
Long-term RVPH plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $39.50MM | $30.80MM | $20.20MM |
| Operating Income | $-39.50MM | $-30.80MM | $-20.20MM |
| Non-Operating Income | $0.26MM | $0.90MM | $0.35MM |
| Interest Expense | $0.03MM | $0.02MM | $0.01MM |
| R&D Expense | $31.42MM | $22.91MM | $11.71MM |
| Income(Loss) | $-39.24MM | $-29.90MM | $-19.85MM |
| Taxes | $0.02MM | $0.02MM | $0.02MM |
| Net Income(Loss)* | $-39.26MM | $-29.92MM | $-19.86MM |
| Stockholders Equity | $5.72MM | $0.81MM | $8.65MM |
| Assets | $23.70MM | $15.50MM | $15.92MM |
| Operating Cash Flow | $-28.32MM | $-33.54MM | $-24.59MM |
| Capital expenditure | $0.00MM | $0.00MM | $0.00MM |
| Financing Cash Flow | $33.17MM | $23.65MM | $25.56MM |
| Earnings Per Share** | $-32.99 | $-18.05 | $-5.48 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.